

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 5 :</b> A61K 37/02, C07K 5/00, 7/00 C07K 15/00, 17/00	<b>A1</b>	<b>(11) International Publication Number:</b> WO 93/17699 <b>(43) International Publication Date:</b> 16 September 1993 (16.09.93)
<b>(21) International Application Number:</b> PCT/US93/01758 <b>(22) International Filing Date:</b> 25 February 1993 (25.02.93)  <b>(30) Priority data:</b> 07/844,716                      2 March 1992 (02.03.92)                      US  <b>(71) Applicant:</b> THE BOARD OF TRUSTEES OF THE LE- LAND STANFORD JUNIOR UNIVERSITY [US/ US]; 900 Welch Road, Suite 350, Palo Alto, CA 94304 (US).  <b>(72) Inventors:</b> CLAYBERGER, Carol, A. ; KRENSKY, Alan, M. ; 812 Mayfield Avenue, Stanford, CA 94305 (US).  <b>(74) Agents:</b> ROWLAND, Bertram, I. et al.; Flehr, Hohbach, Test, Albritton & Herbert, 4 Embarcadero Center, Suite 3400, San Francisco, CA 94111-4187 (US).		<b>(81) Designated States:</b> AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> LYMPHOCYTE ACTIVITY REGULATION BY HLA PEPTIDES  <b>(57) Abstract</b>  Fragments from the polymorphic domains of Class I HLA antigen domains are used to modulate T-cell activity. The pep- tides are from the $\alpha 1$ - or $\alpha 2$ domains, particularly of the HLA-A, and B antigens. The peptides may be conjugated to other com- pounds to be used in diagnosis and therapy. The peptides may block lysis, CTL proliferation or have other regulating effects.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	MI	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

**LYMPHOCYTE ACTIVITY REGULATION BY HLA PEPTIDES****INTRODUCTION****Technical Field**

5       The field of this invention is the regulation of  
cytotoxic T-lymphocytes using peptide fragments from  
Class I HLA peptides.

**Background**

10       Cytotoxic T-cells, particularly cytotoxic  
T-lymphocytes ("CTL"), are restricted in their activity by  
recognizing a specific major histocompatibility complex  
("MHC") antigen on the surface of the target cell, as well  
as a peptide bound in a cleft of the MHC antigen. The  
foreign antigen may be as a result of transplantation from  
an allogeneic host, viral infection, mutation, neoplasia,  
15       or the like. The involvement of the MHC protein appears  
to be essential to the attack by CTL's against the cell  
which includes the foreign antigen. The CTL's by  
monitoring the presence of foreign antigens, are able to  
destroy cells, which if otherwise allowed to proliferate,

would result in the proliferation of pathogens or neoplastic cells.

In monitoring the presence of foreign antigens, the CTL's also recognize transplants of organs, tissue and  
5 cells, which come from allogeneic hosts. In order to protect the transplant from the CTL's, various immuno-suppressive procedures are employed. These procedures are frequently unsatisfactory in not being completely protective and making the patient susceptible to  
10 opportunistic infection.

In view of the very great interest in being able to increase or decrease the numbers of CTL's and their activity, there is substantial opportunity for developing new techniques which would allow for regulating the CTL's,  
15 while still providing substantial protection against pathogens.

#### Relevant Literature

Clayberger, et al., J. Exp. Med. (1985) 11:1709-1714 describe HLA-A2 antigen in comparisons with HLA-Aw68 and  
20 Aw69. Townsend, et al., Cell, (1986) 44:959-968 suggests that CTL recognize segmental epitopes of denatured or degraded proteins in a similar way as helper T-cells. Holmes and Parham, EMBO J., (1985) 4:2849-2854 describe the relationship of HLA-A2, Aw68 and Aw69. CTL target  
25 specificity has been taught to be extremely sensitive to changes in structure of human Class I molecules (Durna and

Pease, Transplantation, (1986) 41:279-285: Biddison, et al., J. Immunol., (1980) 124:548-552: Spits, et al., Immunogenetics, (1982) 16:503-512: Gaston, et al., J. Exp. Med. (1983) 158:280-293).

- 5 Mutants which affect recognition by CTL have been studied in mice (Nathenson, et al., Ann. Rev. Immunol. (1986) 4:471-502: Schulz, et al., Proc. natl. Acad. Sci. USA (1983) 80:2007-2011) and humans, (Krangel, Biochemistry (1982) 21:6313-6321: Krangel, et al., J. Immunol. (1983) 130:1856-1862: Cowan, et al., J. Immunol. (1985) 135:2835-2841: Taketani, et al., *ibid.* (1984) 133:816-821; and Vega, et al., Proc. Natl. Acad. Sci. USA (1985) 82:7394-7398).
- 10

These reports have focused considerable attention on the region between residues 147 and 157, although other regions can also produce functional differences (Ezquerria, et al., J. Immunol. (1985) 134:2727-2733). Clusters of variability have been reported at the carboxy-terminal end of the first extracellular domain and at the amino-terminal end of the second extracellular domain (Ways, et al., J. Biol. Chem. (1985) 26:11924-11933). Sequences between residues 105-108 of all Class I molecules are related to that of the fibronectin binding tetrapeptide (Auffray and Novotny, J. Human Immunology (1986) 15:381-390), which tetrapeptide in either orientation is found to have cell attachment properties (Pierschbacher and Ruoslahti, Nature (1984) 309:30-33; Yamada and Kennedy, J. Cell. Biol. (1985) 28:99-104). Substitution

15

20

25

at position 107 affecting a single monoclonal antibody defined epitope of HLA-A2 has been reported by Salter, et al., J. Exp. Med. (1987) 166:283-288.

#### SUMMARY OF THE INVENTION

5           Methods and compositions are provided based on the sequence of Class I antigen  $\alpha 1$ - and  $\alpha 2$ -domains. These fragments include at least a portion of the amino acids between positions 55 and 120 of the Class I antigens and are used for modulating cytotoxic T-lymphocyte ("CTL")  
10 activity toward target cells. Different peptides may elicit different effects in relation to CTL's or subsets of CTL's.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows the minimum size of peptide sequence  
15 required for inhibition of cytolysis by HLA-A2 specific CTL.

Fig. 2 shows the effect of pretreatment of CTL and of target cells on the inhibition of cytolysis by HLA-A2 specific CTL.

20           Fig. 3 shows the effect of peptide A2.98-113 on release of granules containing serine esterase during cytolysis of target cells by CTL.

Fig. 4 shows the consensus sequence of peptides which constitute the  $\alpha 1$ ,  $\alpha 2$  and  $\alpha 3$  regions of a Class I HLA  
25 molecule, as well as changes in these sequences in different specific HLA molecules.

Fig. 5 shows the effect of peptides from different HLA-A2 epitopes on cytolysis of target cells by CTL of different specificities.

Fig. 6 shows the sensitization of an HLA-Aw69 target cell to cytolysis by clone A2/B17 cells caused by peptide A2.56-69.

Fig. 7 shows the effect on sensitization of incubating target cells or clone A2/B17 cells with peptide A2.56-69.

10

#### DESCRIPTION OF THE SPECIFIC EMBODIMENTS

In accordance with the subject invention, CTL activity in a patient is modulated by administering to the patient a sequence of the polymorphic region of Class I major histocompatibility complex antigens of the host. The polymorphic region comprises the  $\alpha 1$ - and  $\alpha 2$ -domains, with the  $\alpha 1$ -domain being of particular interest, more particularly the residues of the  $\alpha_1$ -helical peptide. The Class I antigens in the human are designated A, B, C, E, F, and G, of which the A, B, E and G antigens are of particular interest.

Besides modulating the activity of CTL's, the subject peptides may also be used for identifying CTL's which bind to the particular peptide, removing particular subsets of CTL's from a T-cell composition or portion thereof and the like. For the most part, the subject compositions will comprise pure compositions or formulated compositions of a peptide of at least 8 amino acids, usually at least 12

amino acids, having a sequence coming within the extended sequence and up to the entire extended sequence:

aa<sup>55</sup> G P E Y W D aa<sup>62</sup> aa<sup>63</sup> T aa<sup>65</sup> aa<sup>66</sup> aa<sup>67</sup> K aa<sup>69</sup> aa<sup>70</sup> aa<sup>71</sup>  
 Q T aa<sup>74</sup> R aa<sup>76</sup> aa<sup>77</sup> L aa<sup>79</sup> aa<sup>80</sup> aa<sup>81</sup> aa<sup>82</sup> aa<sup>83</sup> Y Y N Q S E A G S  
 5 H aa<sup>94</sup> aa<sup>95</sup> Q aa<sup>97</sup> M aa<sup>99</sup> G C D aa<sup>103</sup> G aa<sup>105</sup> D aa<sup>107</sup> R aa<sup>109</sup> L R G  
 aa<sup>113</sup> aa<sup>114</sup> Q aa<sup>116</sup> A Y D G

wherein:

- aa<sup>55</sup> is E or K, particularly E;
- aa<sup>62</sup> is G, Q, E or R, particularly R or G;
- 10 aa<sup>63</sup> is an acidic amino acid or amide thereof, particularly E;
- aa<sup>65</sup> is Q, R or G, particularly Q or R;
- aa<sup>66</sup> is I, N or K, particularly I or K;
- aa<sup>67</sup> is an aliphatic neutral or Y amino acid,
- 15 particularly C, S, V or Y;
- aa<sup>69</sup> is an aliphatic neutral or basic amino acid, particularly A, R or T;
- aa<sup>70</sup> is Q, H, S, N or K;
- aa<sup>71</sup> is an aliphatic neutral amino acid, particularly
- 20 A, L, S or T;
- aa<sup>74</sup> is D, Y or H;
- aa<sup>76</sup> is E, V or M;
- aa<sup>77</sup> is D, S, A, G or N;
- aa<sup>79</sup> is R, Q or G;
- 25 aa<sup>80</sup> is T, I or N;



-7-

aa<sup>81</sup> is an aliphatic non-polar amino acid,  
particularly A or L;

aa<sup>82</sup> is R or L;

aa<sup>83</sup> is G or R;

5 aa<sup>94</sup> is T or I;

aa<sup>95</sup> is a non-polar aliphatic amino acid of from 5 to  
6 carbon atoms;

aa<sup>97</sup> is an aliphatic amino acid or W;

aa<sup>99</sup> is an aromatic amino acid;

10 aa<sup>103</sup> is a non-polar aliphatic amino acid of from 5 to  
6 carbon atoms;

aa<sup>105</sup> is P or S;

aa<sup>107</sup> is G or W;

aa<sup>109</sup> is L or F;

15 aa<sup>113</sup> is Y or H;

aa<sup>114</sup> is H, Q, D, N or R;

aa<sup>116</sup> is Y, D, S, F or H,

which modulates CTL activity.

A subset of peptides of particular interest come  
20 within the following extended sequence:

G S H aa<sup>94</sup> aa<sup>95</sup> Q aa<sup>97</sup> M aa<sup>99</sup> G C D aa<sup>103</sup> G aa<sup>105</sup> D aa<sup>107</sup> R  
aa<sup>109</sup> L R G aa<sup>113</sup> aa<sup>114</sup> Q aa<sup>116</sup> A Y D G

wherein:

aa<sup>94</sup> is T or I;

aa<sup>95</sup> is a non-polar aliphatic amino acid of from 5 to 6 carbon atoms;

aa<sup>97</sup> is an aliphatic amino acid or W;

aa<sup>99</sup> is an aromatic amino acid;

5 aa<sup>103</sup> is a non-polar aliphatic amino acid of from 5 to 6 carbon atoms;

aa<sup>105</sup> is P or S;

aa<sup>107</sup> is G or W;

aa<sup>109</sup> is L or F;

10 aa<sup>113</sup> is Y or H;

aa<sup>114</sup> is H, Q, D, N or R;

aa<sup>116</sup> is Y, D, S, F or H.

Another subset of sequences coming within the above-extended sequence of particular interest are sequences  
15 coming within the extended sequence:

aa<sup>55</sup> G P E Y W D aa<sup>62</sup> aa<sup>63</sup> T aa<sup>65</sup> aa<sup>66</sup> aa<sup>67</sup> K aa<sup>69</sup> aa<sup>70</sup> aa<sup>71</sup>  
Q T aa<sup>74</sup> R aa<sup>76</sup> aa<sup>77</sup> L aa<sup>79</sup> aa<sup>80</sup> aa<sup>81</sup> aa<sup>82</sup> aa<sup>83</sup> Y Y N Q S E A

wherein:

aa<sup>55</sup> is E or K, particularly E;

20 aa<sup>62</sup> is G, Q, E or R, particularly R or G;

aa<sup>63</sup> is an acidic amino acid or amide thereof,  
including E and N, particularly E;

aa<sup>65</sup> is Q, R or G, particularly Q or R;

aa<sup>66</sup> is I, N or K, particularly N or K;

aa<sup>67</sup> is an aliphatic neutral amino acid including V, M, S, C and Y, particularly V;

aa<sup>69</sup> is an aliphatic neutral amino acid including A, T and P, particularly A;

5 aa<sup>70</sup> is Q, H, S, N or K, particularly Q or H;

aa<sup>71</sup> is an aliphatic neutral amino acid including S, A and T, particularly S;

aa<sup>74</sup> is D, Y or H, particularly D or H;

aa<sup>76</sup> is E or V;

10 aa<sup>77</sup> is D, S or N, particularly D;

aa<sup>79</sup> is R or G, particularly G;

aa<sup>80</sup> is T, I or N, particularly T or I;

aa<sup>81</sup> is an aliphatic non-polar amino acid including L or A, particularly L;

15 aa<sup>82</sup> is R or L, particularly R;

aa<sup>83</sup> is G or R, particularly G.

Another series of peptides of at least 8 amino acids of particular interest come within the extended sequence:

Q E G P E Y W D (G or R) (E or N) T (R or Q) (K or N)  
 20 V K A (H or Q) S Q T (H or D) R (V, M or E) (D, S or N) L  
 (G or R) (T or I) (L or A) (R or L) (G or R) Y Y N Q S E  
 A.

Of particular interest are oligopeptides of from about 10 to 25 amino acids having as an active sequence,  
 25 one of the following sequences:

-10-

R (E, V or M) (N or S) L (R or Q) (I, N or T) (A or L) (L or R) (R or G) Y

Other extended sequences from which 8 amino acid fragments are of interest include:

5        T L Q R M Y G C D V G S D W R F L R G,  
          M Y G C D V G S D W R F L R G Y,  
          M Y G C D V G S D G R F L R G Y,  
          G P E Y W D G E T R K V K A,  
          W D R E T Q I C K A K A Q T D R N (N or D) L R (I or  
 10      T) (A or L) L R Y Y,  
          W D R E T Q K Y K R Q A Q T D R V S L R N L R G Y,  
          W D R E T Q I S K T N T Q T Y R E S L R N L R G Y,  
     and  
          W D G E T R K V K A H S Q T H R V D L G T L R G Y.

15        Of particular interest are the shorter sequences:

         R E N L R I A L R Y;  
          R E S L R N L R G Y;  
          R V N L R T L R R Y;  
          R M N L Q T L R G Y  
 20        R E D L R T L L R Y;  
          W D R E T Q I C K A.

Among the sequences of interest are the sequences in the  $\alpha$ 1-domain, namely the amino acid sequence from positions 55-85, more particularly 55-80 or 70-85,

desirably including within the sequence a tetrapeptide DGET, GETR, DRAT, YWDG, RE(N or D)L or (A or L)LRV. Of particular interest for the  $\alpha 2$ -domain is the amino acid sequence from positions 90-112, more particularly 94-116,  
5 desirably including within the sequence a tetrapeptide STWR or SDGR.

The peptides of interest which will serve as the receptor binding peptide will have at least 8 amino acids, usually at least 10 amino acids, more usually at least 12  
10 amino acids, frequently having 15 or more amino acids, and usually not more than about 30 amino acids, more usually not more than about 25 amino acids, desirably having about 12 to 25 amino acids. The amino acid sequence will usually not differ from a naturally occurring sequence by  
15 more than 2 amino acids, or mutations, e.g. deletions or insertions, more usually by not more than about 1 amino acid. The sequence employed will usually be from the polymorphic regions of the C-terminal half of the  $\alpha 1$  domain or the N-terminal half of the  $\alpha 2$  domain of the MHC  
20 antigen of the host of the MHC restricted T-cells, particularly an HLA-A, -B, -E or -G group antigen.

Of particular interest is a sequence or sequence fragment of at least 8 amino acids of the sequence:

G S H T (V, I or L) Q R M Y G C D V G S D (W or G) R  
25 F L R G Y H Q Y A Y D G.

Where there are two or more amino acids indicated at the same site, any of the indicated amino acids may be present.

The region of particular interest will be the region  
5 from amino acid positions 110 to 116.

The subject peptides may be modified in a wide variety of ways. The peptides may be joined by covalent bonds at any convenient site along the peptide to a variety of other compounds for different purposes. Thus,  
10 the peptides may be joined to immunogens for administration to a host for immunization for production of antibodies, or may be joined to a non-adjacent MHC sequence of the particular MHC antigen by means of synthesis, expression of a synthetic gene, or the like;  
15 joined to a lipid or polyalkyleneoxy group; joined to a sugar; or joined to a nucleic acid. Of particular interest is joining the subject peptides to another peptide by synthesis or expression of a synthetic gene where the other peptide provides for extended stability of  
20 the subject peptides when administered to a host. Various peptides may be used, such as the immunoglobulin constant region, e.g. IgGFc. Alternatively, the subject peptides may be joined to a toxin, such as diphtheria toxin, ricin, abrin, etc., particularly where the binding chain has been  
25 removed or inactivated, so as to prevent binding of the binding chain to cells.

The subject peptides may be joined together to provide a single polypeptide having a multiplicity of

activities or may be combined in a mixture to provide the same general activity.

The classes of amino acids are designated as follows:

aliphatic

5 non-polar G, A, P, L, I, V

polar

neutral C, S, T, M, N, Q

acidic D, E

basic K, R

10 aromatic F, H, W, Y

The peptides may be prepared in a variety of ways. Conveniently, they can be synthesized by conventional techniques employing automatic synthesizers, such as the Beckman, Applied Biosystem Inc., or other useful peptide  
15 synthesizer apparatus, or may be synthesized manually. Alternatively, DNA sequences can be prepared which encode the particular peptide and may be cloned and expressed to provide the desired peptide. In this instance a methionine may be the first amino acid.

20 The peptides may also be isolated from natural sources and purified by known techniques, including, for example, chromatography on ion exchange materials, separation by size, immunoaffinity chromatography and electrophoresis. As used herein, the term "a  
25 substantially pure preparation of peptide compound" means a preparation of the peptide which is usually greater than about 70% free of materials with which the polypeptide is naturally associated, and preferably greater than about

80% free of these materials; these materials, however, excludes materials with which the peptide may be mixed in the preparation of pharmaceutical compositions. The sequences may be modified in a variety of ways depending upon their ultimate purpose. Different N- or C- terminal groups may be introduced which allow for linking of the peptide to solid substrates or other molecules. In a synthetic procedure, any molecule may be introduced at the N- or C-terminus which would allow for subsequent reaction, depending upon the purpose for which the peptide is prepared.

For diagnostic purposes, a wide variety of labels may be linked to the terminus, which may provide, directly or indirectly, a detectable signal. For example, fluorescers may be introduced at the terminus or other molecules which provide a linkage to labels such as fluorescers, enzymes, particles, or the like. For example, linkage may be introduced at the terminus, e.g., biotin, which will bind to an avidin conjugate with enzymes or fluorescers. Alternatively, various reactive sites may be introduced at the terminus for linking to particles, solid substrates, macromolecules, or the like. For example, an internal amino moiety of a growing chain bound to a solid substrate with the intermediate side groups protected, may be conjugated with methyldithiobenzoic acid (MDTB). The free mercaptan group may then be used for conjugating with activated olefins. Thus, proteins, such as serum albumin, keyhole limpet hemocyanin, bovine  $\beta$ -globulin, or the like,



may be conjugated to the peptide to provide for an immunogen to produce antibodies to the peptide for use in immunoassays, for affinity chromatography, or the like. Alternatively, the peptide can be bonded to another polypeptide by preparing a DNA sequence which has the peptide at the N-terminus, C-terminus or internal to the protein, so as to provide a fused protein which includes the binding peptide of interest. In this manner, fused proteins may be produced which have enzymatic activity, which enzymatic activity may be modulated by macromolecules, e.g., antibodies, binding to the peptide of interest. Thus, the peptides of the subject invention may be modified in a wide variety of ways for a variety of end purposes while still retaining biological activity.

The subject peptides may also be used in combination with antigenic peptides or proteins of interest to activate CTL's. Thus, the subject peptides may be bound to a protein, either directly or indirectly, so as to be able to present two epitopes to the CTL to which the CTL may bind and be activated. Of particular interest, is where the subject peptides may be bound to a liposome or a bilayer lipid membrane in conjunction with a peptide or protein providing the other determinant site.

Various techniques are available for joining a peptide or protein to a lipid, particularly a phospholipid to provide for the presence of the peptide or protein on the liposome surface. Phosphatidyl choline, phosphatidyl ethanolamine, or other lipid may be used with a

bifunctional linking agent, such as MBSE, glutaraldehyde, methyldithiobenzoic acid, or the like. The formation of liposomes with conjugated proteins finds ample support in the literature, see, for example, U.S. Patent Nos. 3,887,698; 4,261,975 and 4,193,983. The modified peptide or protein is combined with the lipids in an aqueous medium and sonicated to provide the desired liposomes. The liposomes may then be harvested and used in the ways indicated.

10       The subject peptides, by themselves, or in combination with other peptides or proteins, may be used for diagnosing the presence of CTL's which bind to a subject peptide or the combination of a subject peptide and other peptide or protein. In this manner, conjugates of the subject peptide and the antigenic peptide or protein can be prepared by employing linking agents as described previously. Alternatively, the subject peptide and the antigenic peptide may be bound to a solid surface, such as a particle, container surface, or the like. If 15       desired, the subject peptide and antigenic peptide or protein may be conjugated to a particle or protein which is fluorescent. The binding of the particle or protein will allow for sorting and counting in a fluorescence activated cell sorter.

25       The subject peptides may also be used for modulating CTL activity in the mammalian host. The modulation may be by inhibiting CTL activity, particularly inhibiting CTL differentiation, or by sensitizing target cells. This

can be achieved by employing apheresis, where the patient's blood is withdrawn from the patient and circulated through a device in which the peptide is present, either bound to the surface, to remove CTL's active with the subject peptide or in a physiologically acceptable medium to bind to the CTL's and inhibit their activity. Alternatively, the subject peptides may be administered to a host intravascularly, in either an artery or vein, to provide for inhibition or stimulation of the CTL.

Examples of inhibitory peptides are presented infra (see Examples 2 and 9), which are derived from both the  $\alpha_1$  and  $\alpha_2$  domain of HLA-A2. In each case the sequence of the inhibitory peptide correlates with the epitope specificity of the CTL. Moreover, as shown in Example 4, inhibition is mediated by an octapeptide, and occurs by peptide binding to the CTL and not the target cell (see Example 5). Since the inhibitory capacity of the individual peptides correlates with CTL specificity, it seems likely that these peptides inhibit by binding to the variable T cell receptor.

An example of a peptide which stimulates cytolysis of HLA-Class I bearing target cells by alloreactive CTL is presented in Example 10, infra. The simplest interpretation of the results in Examples 10-12 is that the HLA-A2/B17 specific CTL recognize the A2 56-69 peptide in the context of HLA-Aw69 as a restriction element. This implies that the peptide is binding to the HLA-Aw69

molecule. The data and interpretation are similar to those obtained in the influenza (Bastin et al., J. Exp. Med., 165:1508 (1987); Gotch et al., Nature 326:881 (1987)) and xenogeneic systems (Maryanski et al., Nature 5 324:578 (1986)), and demonstrate that alloreactive CTL can recognize Class I derived peptides in a Class I restricted fashion. However, the quantities of peptide required to cause sensitization are significantly larger than those reported in other studies. Although the molecular basis 10 for this is as yet unknown, one possible explanation involves the relative handling of exogenous versus endogenous molecules. For example, HLA is an endogenous molecule, and the exogenous HLA peptides may have to compete with endogenous HLA peptides. Another alternative 15 is that the A2.56-69 peptide may not include all of the residues required for high affinity binding to the target cell.

Two of the CTL epitopes from which the peptides described in the Examples, *infra.* are derived, are 20 situated in very different parts of the HLA-A2 molecule. Residues 62-65 are in an alpha helix which forms part of the peptide binding site (Bjorkman et al., Nature 329:506 (1987)), which is itself thought capable of binding alpha helical peptides. As shown in the Examples, peptides in 25 this region can either inhibit or induce cytotoxicity. In the induction of cytotoxicity, it is possible that the peptide may bind to a target cell HLA Class I antigen and thereby create a structure which is recognized by the CTL.

For example, in the case of A2.56-69 peptide conferring sensitivity to clone A2/B17 cells on HLA-Aw69 cells, the bound peptide presumably substitutes for the  $\alpha$  helix of the  $\alpha_1$  domain, since HLA-Aw69 and HLA-A2 have identical  $\alpha_2$  domains.

In contrast, residue 107 is part of a turn between two strands of  $\beta$  structure at some distance from the alpha helices and peptide binding region (Bjorkman *et al.*, *supra.*) The A2.98-113 peptide may maintain elements of this structure in solution and have little affinity for the peptide binding site of Class I molecules. This interpretation would explain the observation in the Examples that peptides corresponding to this region are inhibitors of HLA-A2 directed cytolysis, but cannot induce cytolysis.

The various activities of the peptides may be determined by appropriate assays. Inhibition of CTLs by peptides may be determined by employing CTL lines specific for a particular HLA in a target cell line carrying the target HLA. The target cell line is labeled, for example, with  $^{51}\text{Cr}$ . These cells are combined in an appropriate medium and the release of the label determined as indicative of the degree of cytolysis. The peptide may be added at the same time as the cells are brought together, may be incubated with the CTLs or may be incubated with the target cell to investigate the mode of action of the peptide.

Instead of using an exogenous marker, one may determine the release of serine esterase activity upon combining the CTLs and the target cells in conjunction with the peptide. The presence of serine esterase activity can be related to the release of granules.

As already indicated, the peptide may be present by itself, or in combination with an antigen thereby providing a different determinant site of interest. Depending upon whether only the subject peptide is included, or the peptide in combination with other peptides, activation or inhibition can be achieved. If irreversible inhibition is desired, the conjugate of the subject peptide with the antigen may be joined to a cytotoxic agent, joined to liposomes containing cytotoxic agents, or joined to a specific monoclonal antibody or immunoglobulin, whereby binding of the conjugate to the CTL will result in the complement mediated lysis of the CTL.

In addition, specific peptides may also serve to block differentiation of CTL, which blocking may be specific or non-specific. The subject peptides may also be used to modulate CTL activity, wherein modulation includes inhibiting cytolytic activity, where the inhibition may be reversible or irreversible. In some instances, the subject peptides may be used for determining the presence of particular sets or subsets of MHC-restricted CTL's.

The subject peptides also bind to at least one cellular protein of about 27kD. The protein is expressed in CD8+ T cells and appears to be a surface membrane protein. The protein can be obtained in substantially pure form, but gel electrophoresis separation and identification with one of the peptides according to the subject invention, by purification with an affinity chromatography column using a subject peptide, or the like. Purities in excess of 50% by weight, or greater, can be achieved in accordance with known methods. When the subject peptides are bound to a well surface, the T cells rapidly bind to the walls of the well. The protein or active fragments thereof can be used to reverse the effect of the subject peptides on cellular processes, can be used for screening of active peptides and can be used to make antibodies to identify cells expressing the protein. The protein or active fragments thereof may be used to modulate the activity of CTL, such as inhibiting activation, lysis of other cells or other interactions with other cells resulting in stimulation or inactivation of the other cells.

These various capabilities may be achieved by combining cellular compositions comprising CTL's with the peptide in sufficient amount to provide the desired property. Where separation is desired, affinity columns, conjugated beads, e.g. magnetic beads, or other technique may be used, where the peptide-bound cells may be

-22-

separated from other cells which are either not bound or non-specifically bound.

The subject peptides, by themselves or as conjugates, may be prepared as formulations in pharmaceutically acceptable media, for example saline, PBS, and glucose, generally at a pharmacologically effective dose, the concentrations of which will be determined empirically in accordance with conventional procedures for the particular purpose. The additives may include bactericidal agents, stabilizers, buffers, or the like. The amount administered to the host will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, whether inhibition or activation is desired, the state of the host, the manner of administration, and the like. In order to enhance the half-life of the subject peptide or subject peptide conjugates, the peptides may be encapsulated, introduced into the lumen of liposomes, prepared as a colloid, or other conventional technique may be employed which provides an extended lifetime of the peptides.

The following examples are offered by way of illustration and not by limitation.

#### EXAMPLES

##### Example 1

##### 25 Preparation of Peptides Derived From HLA-A2

Four peptides were prepared by conventional synthetic methods using standard solid-phase methods. See Erickson



& Merrifield in: The Proteins Vol. 2, 3rd edition (eds. Neurath, H. & Hill, R.L.) p. 255-527 (Academic Press, N.Y. 1970), which is hereby incorporated herein by reference. Three of the peptides had amino acids from the  $\alpha_2$  domain and one of the peptides had amino acids from the  $\alpha_1$  domain of a HLA-A2 antigen. The four peptides had the following compositions and designations:

A2.56-69 G P E Y W D G E T R K V K A

A2.94-112 T L Q R M Y G C D V G S D W R F L R G

10 A2.98-113 M Y G C D V G S D W R F L R G Y

Aw.68 98-113 M Y G C D V G S D G R F L R G Y

The designations indicate the major histocompatibility antigen from which the peptide is derived, and the position of the amino acids in the antigen.

15 Example 2

Inhibition of HLA-A2 Specific CTL by Peptides Derived from HLA-A2.98-113 and HLA-A2.94-112

Peptides prepared as in Example 1, i.e., those corresponding to HLA-A2.56-69, HLA-A2.94-112, HLA-A2.98-113, and HLA-Aw 68.98-113, were preincubated for 30 min. with  $1-3 \times 10^3$  CTLs before addition of  $10^3$  CPM of  $^{51}\text{Cr}$ -labeled B-lymphoblastoid target cells. The cytotoxicity assay was then performed as described by Clayberger et al., J. Exp. Med. (1984) 162:1709-1714; and Reiss et al., Proc. Natl. Acad. Sci. USA (1980) 77:5432-5436, which are hereby incorporated herein by reference.

In the first study, the CTL cell line was AJY, a long term CD8<sup>+</sup> CTL line specific for HLA-A2, and the target cell was the B-lymphoblastoid cell line JY (HLA-A2, B7). In the second study the CTL was PWSB, a bulk culture with reactivity against HLA-B17 and the target was FMB, which expresses HLA-A1, A32, B17. In each case the percentage of specific release obtained in the absence of peptide was determined. The lower amount of specific release in the second study potentially made cytotoxicity more sensitive to inhibition. Stocks of peptides at 1 mg/ml in PBS were diluted to give final concentrations in the assay as indicated in Table 1. As a control inhibitor, the monoclonal antibody PA2.6 which is directed against the monomorphic determinant of HLA-A, B, 6 molecules was used (Reiss *et al.*, *supra*: McMichael, *J. Exp. Med.* (1980) 152:195s-203s). The peptides employed were A2.98-113, A2.94-112, Aw68.94 112 and A2.56-69. The following table indicates the results.

Table 1.

Concentration <u>μg/ml</u>	% Specific Lysis			
	A2.98-113	A2.94-112	Aw68.94-112	A2.56-69
Trial 1. 160	0	3	52	51
CTL=AJY 80	4	20	45	38
Target=JY 40	18	35	63	61
Trial 2. 160	27	35	28	20
CTL=PWSB 80	29	32	30	27
Target=FMB 40	30	34	35	31

In the first case, the percentage specific release-  
obtained in the absence of peptide was about 54, while in  
the second case it was about 28.

The above results with CTL which are restricted by  
the HLA-A2 antigen, show inhibition of specific  
cytotoxicity. With CTL's not restricted by A2, lysis of  
random target cells occurs with the results approximating  
the standard specific release obtained in the absence of  
peptide. These results suggest that the tryptophan at  
position 107 may be critical. Peptide A2.98-113 and  
peptide Aw68.98-113 are homologous except for the  
substitution of glycine for tryptophan at this position;  
this substitution resulted in a loss of inhibition of  
cytolysis by HLA-A2 specific CTL.

The results of treatment of peptide A2.98-113 with  
different proteases, i.e., trypsin or chymotrypsin, allow  
the suggestion that arginine 108 is of importance, but  
that peptides 109-113 are not critical. The major sites

of action of trypsin and chymotrypsin are Arg, Lys, and Trp, Phe, Tyr, respectively. Chymotryptic, but not tryptic, cleavage of the peptide reduced the inhibitory activity (results not shown).

5     Example 3

Effect of Specificity of CTL and Target Cell on Inhibition  
      of Cytolysis Caused by HLA-Derived Peptides

      A number of different CTL cell lines were studied, where the specificity of the cell lines were varied. The  
10     results shown in Table 2 indicate that only where the CTL's and the target cells share A2 specificity do the A2-derived peptides provide inhibition.

Table 2

Specificity of CTL Tests for Inhibition by Peptides

CTL	Specificity of CTL	Target Cell	Target Molecule	A2.98-113	A2.94-112	Inhibition of Lysis by Peptide Aw68.98-113	A2.56-69
Line AJY	A2	JY	A2	+	+	-	-
Line PJY	A2	JY	A2	+	+	-	-
Clone A20.1	A2	JY	A2	+	+	-	-
Clone AI.10	A2	JY	A2	+	+	-	-
Clone AI9.1	A2, Aw68, Aw69	JY	A2	+	+	-	-
Line PWSB	A2, B17	JY	A2	+	+	-	-
Line PWSB	A2, B17	FMB	B17	-	-	-	-
Clone AL8.1	Aw68, Aw69	LB	Aw68	-	-	-	ND
Clone A15.1	Aw69	IDF	Aw69	-	-	-	ND
Line CJY	Dr6	Jy	DR6	-	ND	-	-
Line CJY	Dr6	DAUDI	Dr6	-	ND	-	-

The specificity of the CTL is based upon analysis of the pattern of killing on a panel of B lymphoblastoid cell lines and by patterns of inhibition with monoclonal antibodies. ND indicates not done. CTL used were from four different donors.

Example 4Minimum Peptide Sequence Required for Inhibition of HLA-A2 Specific CTL

5 The minimum peptide sequence required for inhibition of cytolysis by HLA-A2 specific CTL was determined by examining the effect of size on the inhibition.

A series of peptides which started at positions 98-104 and ended at position 108 of HLA-A2 or HLA-Aw68 were synthesized. The effect of these peptides on  
10 cytolysis of JY cells (HLA-A2, B7, DR4,6) by seventeen different HLA-A specific lines or clones were tested. The HLA-A2 specific lines or clones were generated as described in Clayberger *et al.*, *supra*. Peptides (200 mg/ml) were preincubated with  $1-3 \times 10^3$  CTL for 30  
15 minutes prior to addition of  $10^3$  CPM of  $^{51}\text{Cr}$ -labeled target cells. The peptides were present throughout the cytotoxicity assay which was performed as described in Clayberger *et al.*, *supra*, and in Krensky *et al.*, *Proc. Natl. Acad. Sci. USA* 79:2365 (1982), which are hereby  
20 incorporated herein by reference. Peptides were prepared as stock solutions at 1 mg/ml in phosphate buffered saline and diluted in complete medium (MEM supplemented with 10% calf serum) to give the final concentration used.

The results on the inhibition of cytolysis by CTL-A2  
25 is shown in Fig. 1A, where inhibition is expressed as  $(1 - [\text{specific cytolysis in the presence of peptide} / \text{specific cytolysis in the absence of peptide}]) \times 100$ .

As seen in the figure, peptide 104-108 did not inhibit, peptides 102-108 and 103-108 caused weak inhibition, and the remaining peptides caused good inhibition of cytolysis. Thus, an octapeptide comprising  
5 residues 101-108 was sufficient to cause the inhibitory effect. A major decrease in the inhibitory effect occurs with loss of the cysteine at position 101. This loss may be due to the loss of disulfide cross-linking of two peptide molecules when cysteine 101 is absent.

#### 10 Example 5

##### Locus of Action of Peptide A2.98-113

The locus at which peptide A2.98-113 interacts to cause an inhibitory effect on HLA-A2 specific CTL mediated cytolysis, i.e., with the CTL and/or with the target cell,  
15 was determined as follows.

The CTL ( $1 \times 10^6$  CTL-A2) and/or the target cells ( $^{51}\text{Cr}$ -labeled JY target cells) were incubated with 100  $\mu\text{g}$  of A2.98-113 for 30 min. at 37°C, or alternatively with the control peptide, Aw68.98-113. The sequences of these  
20 peptides are presented in Example 1. As an additional control, the cells were incubated with complete medium minus peptide. Following the incubation, the cells were washed three times in complete medium, and tested in a  $^{51}\text{Cr}$ -release assay (see Example 2).

25 The results are presented in Fig. 2, where it may be seen that lysis was inhibited when the CTL, but not the target cells, were pretreated with A2.98-113. Inhibitory

effects were not observed when CTL or target cells were pretreated with the control peptide, Aw68.98-113.

#### Example 6

##### Mechanism of Inhibition of CTL by A2.98-113 Effect on CTL

##### 5 Viability

To determine whether CTL were inhibited due to their autolysis induced by A2.98-113, either  $^{51}\text{Cr}$ -labeled CTL-A2 cells or unlabeled CTL-A2 cells were incubated with the peptide for 6 hours at 37°C in complete medium. During  
10 the 6 hour incubation there was no detectable decrease in cell viability as judged by exclusion of trypan blue or by  $^{51}\text{Cr}$ -release (results not shown).

#### Example 7

##### Mechanism of Inhibition of CTL by A2.98-113 Effect on

##### 15 Release of Granules Containing Serine Esterase

The effect of A2.98-113 on release of granules containing serine esterase during cytolysis of target cells by CTL was determined as follows.

The specificity of release was determined by  
20 incubating  $3 \times 10^5$  HLA-A2 specific CTL with JY cells (HLA-A2; B7; Dr4,6) or IBW4 cells (HLA-A3; B35; DR1) for 2 hours in V bottom microtiter wells. The ratios of CTL:target cells were 1:0.01, 1:0.05, 1:0.10, 1:0.5, and 1:1. After the incubation, the plates were spun at  
25 1000 RPM for 2 minutes, and the supernatant was assayed for serine esterase activity essentially as described in



Young et al., Cell 47:183 (1986), which is hereby incorporated herein by reference. The reaction mixtures consisted of 20  $\mu$ l of supernatant plus 200  $\mu$ l of substrate (2 x 10<sup>-4</sup> M N-benzyloxycarbonyl-L-lysine thiobenzyl ester, 5 2.2 x 10<sup>-4</sup> M nitrobenzoic acid, 0.1M Tris-HCl, pH 8.0). After 30 min. at 37°C, the absorbance was determined at 410 nm. Total serine esterase activity was determined by substituting 0.01% Triton X-100 for stimulator cells. The results, shown in Fig. 3A, indicate that release of the 10 granules occurred when the HLA-A2 specific CTL were incubated with JY cells (closed circles), but not when the HLA-A2 specific CTL were incubated with IBW4 cells (closed squares).

The effect of peptide A2.98-113 on release of 15 granules containing serine esterase was determined in a similar fashion, except that the HLA-A2 specific CTL were preincubated with 100  $\mu$ g of peptide, either A2.98-113 or Aw68.98-113, or with only complete medium, for 30 min. at 37°C prior to the addition of JY target cells at ratios of 20 CTL:target cells of 1:0.01, 1:0.05, 1:0.1, 1:0.5 and 1:1.

As seen in Fig. 3B, complete inhibition of esterase release was seen with 100  $\mu$ g/ml of A2.98-113 at an effector-to-target ratio of 1:0.1 (closed squares). The control peptide Aw68.98-113 had no effect on esterase 25 release (closed triangles), since release in this case was equal to that obtained with control cells preincubated with complete medium (closed circles).

These results, in conjunction with those in Example 5 indicate that the A2.98-113 peptide blocks events which occur early in T cell activation by binding directly to the CTL. This binding may be to the antigen receptor.

5     Example 8

Isolation of CTL Specific for the Epitope Shared by HLA-A2  
and HLA-B17, for HLA-B17, and for HLA-A2

          CTL with the various specificities were derived from the peripheral blood lymphocytes of a normal donor  
10     (HLA-A3; B7; DR6) essentially as described by Clayberger et al. (1985), *supra*. For CTL specific for the epitope shared between HLA-A2 and HLA-B17, the cells were stimulated in primary culture with the irradiated (10,000R) B-lymphoblastoid cell line Mag (HLA-A26,33;  
15     B17,51) and cloned using the SB cell line (HLA-A1,2; B17,44; DR2,6) as stimulators. CTL specific for B17 were derived from the same primary culture, but were cloned using the SH cell line (HLA-A3,w33; B7,17(w57)) as stimulators. HLA-A2 specific CTL were derived from cell  
20     stimulated in primary culture with the JY cell line and cloned using the Herluff cell line (HLA-A2; B12,35; DR4,7) as stimulators. The fine specificity of these CTL clones was assessed using a panel of 11 targets expressing HLA-B17, 8 targets expressing HLA-A2 and 15 targets with  
25     unrelated HLA molecules. Multiple clones of the desired specificities were obtained. An individual clone which caused cytolysis of both HLA-A2 type target cells and

-33-

HLA-B17 type target cells was designated clone A2/B17. The cytolysis of target cells of clone A2/B17 was inhibited by antibody MA2.1. A second clone, which lysed all HLA-B17 target cells but no others was designated B17.

- 5 A third clone, which lysed all HLA-A2 target cells but no others was designated CTL-A2.

The target specificity of clone A2/B17 and the finding that cytolysis by this clone was blocked by monoclonal antibody MA2.1 indicates that cells of clone  
10 A2/B17 recognize the epitope shared by HLA-A2 and HLA-B17.

#### Example 9

#### The Effect of Peptides from Different HLA-A2 Epitopes on Cytolysis of Target Cells by CTL of Different Specificities

- 15 Examples 2-7, *supra*, have involved the effects of peptides derived from the region around tryptophan 107 in the  $\alpha_2$  domain. This residue, which is on a bend between two strands of  $\beta$  pleated sheet (Bjorkman *et al.*, (1987), *supra*), is critical for a major serologic epitope of  
20 HLA-A2. Salter *et al.*, *J. Exp. Med.* 166:283 (1987); Layet *et al.*, *J. Immunol.* 138:2197 (1987).

- Another important epitope involves residues 62-65 of the  $\alpha$  helical region of the  $\alpha_1$  domain. Bjorkman *et al.*, *supra*. This epitope was originally defined by the  
25 monoclonal antibody MA2.1 (McMichael *et al.*, *Hum. Immunol.* 1:121 (1980)), and is shared by all known subtypes of HLA-A2 and HLA-B17 (Ways and Parham, *Biochem. J.* 216:423

(1983)). A comparison of the amino acid sequence of HLA-A2 and HLA-B17 and eight other HLA-A,B,C proteins showed that only the glycine residue at position 62 is unique, suggesting that this residue contributes to a shared determinant (Ways et al., J. Immunol. 137:217 (1986)).

Peptides derived from the above two regions were examined for their inhibitory effect on cytotoxicity of target cells by CTL with different HLA specificities, i.e., those of clone A2/B17, clone CTL-A2, and clone B17 (see Example 8, *supra*). CTL were incubated with the following peptides: A2.56-69, Aw68.56-69, A2.98-113, or Aw68.98-113.

The epitopes studied and peptides used in the study are shown in Fig. 4, where the protein sequences in the three extracellular domains ( $\alpha_1$ ,  $\alpha_2$  and  $\alpha_3$ ) of eight HLA-A,B molecules are shown using the standard one letter amino acid code. The sequence of HLA.Bw58 subtype of HLA-B17 is from Ways et al., J. Biol. Chem. 260:11924 (1985), that of HLA-A3.1 is from Strachen et al., EMBO J. 3:887 (1984), and the remaining sequences of the HLA-A2/28 family are from Holmes et al., J. Immunol. 139:936 (1987). Peptides A2.56-69 and Aw68.56-69, and A2.98-113 and Aw68.98-113, which are derived from  $\alpha_1$  and  $\alpha_2$ , respectively, are indicated by cross-hatching. The two residues found to be critical for the epitopes shared by subtypes of HLA-A2 and HLA-B17 (glycine 62) and subtypes HLA-A2 and HLA-Aw69 (tryptophan 107) are indicated by stippling and the

-35-

vertical arrows. The consensus sequence is derived from a total of 23 HLA-A,B,C sequences.

The CTL were incubated with peptides at concentrations of 100  $\mu\text{g/ml}$ , 200  $\mu\text{g/ml}$ , or 300  $\mu\text{g/ml}$ .  
5 Control samples were incubated in the absence of peptide. The final molar concentrations of peptides used in the assay at 100  $\mu\text{g/ml}$  were  $4.9 \times 10^{-5}\text{M}$  for A2.98-113;  $5.2 \times 10^{-5}\text{M}$  for Aw68.98-113;  $5.9 \times 10^{-5}\text{M}$  for A2.56-69; and  $5.9 \times 10^{-5}\text{M}$  for Aw68.56-69. The CTL cells were incubated  
10 with the peptides for 20 min. prior to the addition of  $10^3$   $^{51}\text{Cr}$ -labeled T7529 cells (HLA-Aw33; B17(w58); DR6) or JY cells (HLA-A2; B17; DR4,6). In all cases, the effector-to-target ratios were 1:1.

The results on cytotoxicity, as measured by  $^{51}\text{chromium}$  release from the target cells, is shown in Fig. 5.  
15 Figures 5A and 5B show the results of the effects of the peptides on cells of clone A2/B17; Fig. 5C shows the effects on cells of clone B17, and Fig. 5D on CTL-A2. The peptides are indicated as follows: (open circles)  
20 A2.56-69; (open squares) Aw68.56-69; (open triangles) Aw.98-113; and (closed squares) Aw68.98-113. Peptide A2.56-69, which encompasses the shared serologic epitope, specifically inhibited the killing of both HLA-A2 and HLA-B17 expressing target cells by clone A2/B17 cells. In  
25 contrast, this peptide had no effect upon the lysis of HLA-B17 expressing cells by clone B17 cells. Clone A2/B17 cells were not inhibited by a peptide derived from residues 56-69 of HLA-Aw68.1, or by a series of unrelated

-36-

peptides. The A2.98-113 peptide did not affect the lysis of HLA-B17 expressing targets by clone A2/B17 cells, but some inhibition was observed at high concentrations with HLA-A2 expressing targets. This difference indicates that the epitopes of HLA-A2 and HLA-B17 recognized by clone A2/B17 cells are not precisely the same.

These results show that the capacity of peptides to inhibit alloreactive CTL is not restricted to the region involving residues 101-108 of the  $\alpha_2$  domain, and that they may be derived from a second epitope of HLA-A2.

The discrepancy of the results achieved with peptide A2.56-69 using clone A2/B17, and those with the PWSB cell line (see Table 2) with respect to the inhibitory effect of this peptide may be explained by the polyclonal nature of the PWSB cells. That is, the PWSB line probably is a mixture of CTL's including individual clones specific for HLA-A2 or HLA-B17.

#### Example 10

##### Sensitization of Target Cells to CTL caused by a HLA-2 Derived Polypeptide

Clone A2/B17 was incubated with peptide A2.56-69 and  $^{51}\text{Cr}$ -labeled target cells at an effector-to-target ratio of 5:1 for 5 hours, after which  $^{51}\text{chromium}$  released was measured. The concentrations of peptide were 10, 30, 100, and 300  $\mu\text{g/ml}$ . The results of the effect of peptide on the percent of specific lysis of the target cells by clone A2/B17 cells are presented in Fig. 6. The target cells

-37-

were: (closed square), IBW4 (HLA-A3; B35; DR1); (closed triangle), LB (HLA-Aw68.1; B40, DR6); (closed circle), Pally (HLA-Aw68.2,26; B14,38; DR1,4), or (open diamond), IDF (HLA-Aw69,26; B15, 38, DR5).

5           In the absence of peptide, clone A2/B17 cells do not lyse targets expressing HLA-Aw69, HLA-Aw68.1, and HLA-Aw68.2 (data not shown). The inability of clone A2/B17 cells to lyse these targets is due to the differences in the critical residues around position 62  
10       from those found in HLA-A2 and HLA-B17. However, when peptide A2.56-69 was included in the cytotoxicity assay, there was significant lysis of HLA-Aw69 expressing targets by A2/B17 cells (Fig. 5). In contrast, targets expressing HLA-Aw68.1, HLA-Aw68.2, or the unrelated HLA-A3 molecule  
15       were not lysed.

          Lysis of HLA-Aw69 cells by clone A2/B17 cells in the presence of peptide A2.56-69 was blocked by monoclonal antibody DR11-351, which only binds to the HLA-Aw69 of the target cell. In contrast, the monoclonal antibody MA2.1  
20       did not inhibit lysis (results not shown). MA2.1 binds to the epitope of HLA-A2 and HLA-B17 formed by residues 56-69, but does not bind to the HLA-Aw69 or peptide A2.56-69. These results demonstrate the involvement of the HLA-Aw69 molecule in the sensitization by peptide  
25       A2.56-69.

          The addition of A2.98-113 peptide to B cell lines which do not express HLA-A2 did not cause sensitization to lysis when target cells expressing a variety of HLA

-38-

molecules were used. This was true even though a wide range of peptide concentrations (0.1 to 300 µg/ml were used.)

In binding A2.56-69, the HLA-Aw69 molecule is able to present an epitope that mimics the native structure of HLA-A2. That HLA-Aw69 but not other members of the HLA-A2/28 family can be sensitized is of interest. HLA-Aw69 is a recombinant molecule having  $\alpha_1$  derived from HLA-Aw6B and  $\alpha_2$  and  $\alpha_3$  derived from HLA-A2.1 (Holmes and Parham, EMBO J. 4:2849 (1985)). Thus, HLA-2.1 and HLA-Aw69 differ by only 6 amino acids, all residing in the  $\alpha_1$  domain and three of which are present in the A2.56-69 peptide.

#### Example 11

##### Locus of Peptide Interaction in Sensitization

To assess whether sensitization resulted from peptide interaction with the CTL or the target, cells were pretreated with A2.56-69, washed and then tested for cytolysis. More specifically,  $1 \times 10^6$  clone A2/B17 cells or  $^{51}\text{Cr}$ -labeled IDF (HLA-Aw69,26; B18,38; DR5) were incubated with 100 µg of peptide or medium for 30 min. at 37°C, washed three times, and cytotoxicity as determined by  $^{51}\text{chromium}$  release was measured.

As seen from the results presented in Fig. 7, target cells expressing HLA-Aw69 were lysed when the targets, but not the CTL, were pretreated with A2.56-69.



Example 12Effect of Peptide A2.56-69 on Release of Granules  
Containing Serine Esterase

The effect of peptide A2.56-69 on the release of  
5 granules containing serine esterase during co-culture of  
A2/B17 cells with HLA-Aw69 expressing cells may be  
performed essentially as described in Example 7, *supra*,  
except that the CTL are from clone A2/B17, the target  
cells are those expressing HLA-Aw69, and the cells are co-  
10 cultured in the absence or presence of peptide A2.56-69.

Example 13Effect of a Variety of HLA Peptides of Amino Acids 60-84  
and HLA-B 2702/05.145-169 on Lysis

These peptides were synthesized and had the following  
15 sequence:

HLA-B2702.60-84	WDRETQICKAKAQTDRENLRALRY
HLA-B2705.60-84	WDRETQICKAKAQTDREDLRTLRY
HLA-Bw46.60-84	WDRETQKYKRQAQTDREVSLRNLRGY
HLA-Bw62.60-84	WDRETQISKTNLTQTYRESLRNLRGY
20 HLA-A2.1.60-84	WDGETRKVKAHSQTHRVDLGLTLRGY
HLA-B2702/05.145-169	RKWEAARVAEQLRAYLEGECEVWLR
HLAB38.60-84	WDRNTQICKTNLTQTYRENLRALRY

The effect of the above sequences on lysis of long-  
term CTL specific for HLA-A2, -B2705, -Bw46, -Bw62, and  
25 -Cw4 was determined as described in Examples 2 and 3, and  
also included CTL specific for HLA-B27 and the HLA-Cw4.  
None of the peptides inhibited or enhanced lysis with the

-40-

exception of the B2702.60-84 peptide. This peptide blocked lysis by all CTL, regardless of their HLA specificity. This effect was due to interaction with the CTL and not the target cell as shown by pre-treatment experiments (as in Example 5).

These peptides were tested for effects on the differentiation of CTL from CTL precursors in limiting dilution assay. The procedure was modified from Skinner and Marbrook (J. Exp. Med. 143:1562; 1976) as follows:

10 PBL from normal HLA-typed donors were purified over Ficoll-Hypaque and co-cultured in round bottom microtiter wells with irradiated (10,000 R) EBV transformed B-lymphoblasts expressing the HLA allele of interest. Responder PBL were added at 3000, 6000, 10000 and 30000

15 cells per well while stimulators were added at 6000 cells per well. 20-4 replicates were set up for each concentration of responder cells in RPMI-1640 medium supplemented with 10% fetal bovine serum plus L-glutamine. Plates were incubated for six days in a 5% CO<sub>2</sub>/95% air

20 humidified incubator at which time the contents of each well were mixed by pipetting five times with a multi-channel pipette. Fifty microliter aliquots were transferred to the V-bottom microtiter wells to which 1000 <sup>51</sup>Cr labeled targets of known HLA type were then added.

25 Lysis was determined in a four-hour cytotoxicity assay (Example 2). Wells were designated positive if specific lysis was >10%. CTL precursor frequency was determined by linear regression analysis using a computer program.

The B2702.60-84, Bw46.60-84 and Bw62.60-84 peptides all blocked the differentiation of CTL, whereas the other peptides had no effect.

Effect of Peptides Corresponding to HLA Regions

5           on CTL Precursor Frequency as Determined by  
                   Limiting Dilution Analytis

	<u>Peptide</u>	<u>1/CTL Precursor Frequency</u>
	B2705.60-84	164,245
	B2702.60-84	3,349,990
10	B38.60-84	3,334,937
	A2.160-84	164,245
	Bio46.60-84	2,995,400
	Bio62.60-84	2,995,400
	B27.145-169	164,245

15           PBL from a normal donor (HLA-A3; B-7, 38; Cw4; DR4,6) were cultured with ty (HLA-A2; B7; DR4,6) or HOM2 (HLA-A3; B27) in the presence of 10-100 µg/ml peptide. After 6 days, lysis was tested on <sup>51</sup>Cr-labeled CIR cells expressing either HLA-A2.5 or HLA-B2705. Results are shown for

20   HLA-A2 specific lysis but similar results were obtained for HLA-B27 specific lysis.

The effect was not allele specific since the differentiation of CTL specific for a number of different HLA molecules was inhibited. None of the peptides

-42-

affected Class II restricted responses, including mixed lymphocyte responses and mitogen induced proliferation.

PBL from normal donors were cultured at  $5 \times 10^5$  cells/round bottom microtiter well in RPMI-1640 supplemented with 10% fetal bovine serum and L-glutamine. Cultures were supplemented with either  $5 \times 10^3$  irradiated (10,000 R) PBV transformed B lymphoblasts or 10  $\mu$ g/ml phytohemagglutinin P (PHA-P). Cells were incubated at 37°C for 3 days for PHA-P and 5 days for alloantigen at which point  $^3\text{H}$ -thymidine was added (2  $\mu$ li/well). After 16 hours wells were harvested and  $^3\text{H}$ -thymidine incorporation determined by scintillation counter.

#### Example 14

##### Effect of Truncated Sequences on Lysis and Differentiation

Since the B2702.60-84 and B2705.60-84 peptides differed by only 3 amino acids, additional peptides were prepared to investigate the effect of these differences. Three additional peptides were synthesized:

HLA-B2702.75-84	RENLRIALRY
HLA-B2705.75-84	REDLRTLLRY
HLA-B2702/05.60-69	WDRETQICKA

Following the procedures described in Example 13, the peptide corresponding to residue 60-69 of HLA-B2702/05 had no effect on the assays described above. The peptide corresponding to residue 75-84 of HLA-B2702 blocked all Class I specific CTL responses, whereas the peptide corresponding to the same region of HLA-B2705 did not.

To determine which residue(s) mediated the inhibitory effects, 3 more peptides were synthesized in which single amino acid changes were introduced at residues 77, 80 and 81 to convert the B2702 sequence into the B2705 sequence at that position. The B2702.75-84(D) and B2702.75-84(L) peptides still blocked lysis by existing CTL and differentiation of pre-CTL while the B2702.75-84(T) peptide had no inhibitory activity. Thus, the isoleucine at position 80 is required for inhibition.

10	HLA-B2702.75-84(D)	REDLRIALRY
	HLA-B2702.75-84(T)	RENLRITALRY
	HLA-B2702.75-84(L)	RENLRILLEY

It was also found by the following assay that B2702.60-84, B38.60-84 and B2702.75-84 when pre-bound to plastic caused cells to bind. None of the other peptides were found to have this effect. However, when the B2702.60-84 peptide was conjugated to bovine serum albumin or to beads via the cysteine at residue 67, the blocking effect and the ability to bind cells to plastics were lost.

The plastic binding procedure was as follows: peptide (100  $\mu$ g/ml) was dissolved in PBS and 50  $\mu$ l was added to round bottom microtiter wells or 5-10  $\mu$ l to petri dishes. After 60 minutes at 37°C or overnight at 4°, the solution was removed and the plates washed twice in RPMI-1640 supplemented with 10% fetal bovine serum. Cells were added and incubated at 4° for 30 minutes. Binding to petri dishes was determined by inspecting the dishes under

a microscope following gentle agitation. Binding to microtiter wells was determined after centrifugation at 500 rpm for 3 minutes. Cells which did not bind formed a small pellet at the bottom of the well whereas cells that  
5 did bind did not form a pellet.

Binding occurred equally well at 4°, 25°, or 37° and was not dependent on exogenously added divalent cations since binding was observed in medium containing EDTA. However, if cells were preincubated with 1% NaN<sub>3</sub> or fixed  
10 with paraformaldehyde, no binding was observed, indicating that viable cells and most likely generation of ATP were required.

#### Example 15

#### Effect of Peptides on Prolongation of Rat Heterotopic 15 Heart Graft Survival

To study the effect of peptides, by themselves or with immunoinhibitory drugs, DA or Lewis rats received an abdominal heterotopic heart allograft from a PVG (guinea pig) donor. Graft recipients (10 to 12 per group) were  
20 either not treated (Group i) or received different regimens (Groups ii to vi). Graft survival was assessed by palpation of transplant heart beat. Group ii animals were injected with 2 - 10 mg B2702.75 - 84, I.V., 7 - 10 days prior to transplant. A slight but significant  
25 prolongation of graft survival was observed in Group ii treated animals.

Group iii animals were treated with a sub-therapeutic dose of cyclosporine A (CsA) (20mg/kg, orally, daily on days 0 - 4). These animals rejected their grafts by day 15 after transplantation. Group iv animals were treated with 10 mg per rat of B.2702-75-84, 7 days and 1 day prior to transplantation, given a heart allograft on day 0 and then treated as in group iii with CsA (20 mg/kg) on days 0 -4. A very significant prolongation of graft survival was observed with approximately %40 of these animals maintaining their grafts for more than 100 days.

Group v animals were treated with a sub-therapeutic dose of anti-thymocyte globulin (ATG, 20 mg/kg I.V. on days -3 and -2) as in group v and 10 mg I.V. of B.2702.75-84 on days -1 and 0, and given a heart allograft on day 0. These animals also showed significant prolongation of their graft.

In addition, more than %60 of the rats have maintained their grafts for >100 days when treated with the peptide B7.75-84 (R E S L R N L R G Y). It should be noted that the peptides employed are human HLA peptides and not rat peptides. Nevertheless, these peptides show profound activity.

The following table tabulates the results.

**Table.** Prolongation of rat heterotopic heart graft survival by B.2702.

	DAY OF REJECTION	MEAN
(i) No treatment	6, 6, 6, 7, 7, 8, 8, 8, 8, 8	7.25
(ii) B.2702 only	8, 8, 8, 8, 9, 9, 10, 10, 10, 10, 10	9.17
(iii) CsA only	10, 12, 12, 14, 15, 15, 15, 16, 16, 20	14.5
(iv) CsA + B.2702	22, 22, 23, 24, 25, 25, 25, >100, >100, >100, >100, >100	ND
(v) ATG	10, 10, 11, 11, 11, 11, 12, 12, 12, 13	11.3
(vi) ATG + B.2702	12, 12, 13, 13, 18, 18, 20, 20, 20, >100, >100, >100	ND



**Table.** Statistical significance of heart transplant experiments.

	Long-Rank Test P value	Wilcoxon Test P value
(ii) versus (i)	0.0001	0.0002
(iv) versus (iii)	0.0001	0.0001
(v) versus (iv)	0.0001	0.0001

Example 16

B.2702.75-84 Peptide Binding to Cellular Protein

Cells were radiolabeled and lysates were bound to microtiter wells coated with B.2 or irrelevant peptides.  $10^8$  CD8+ T cells were depleted of internal stores of cysteine and methionine by preculturing them for 4 h in cysteine-methionine free RMPI-1640 supplemented with 10% dialyzed fetal bovine serum and 1mM L-glutamine.  $^{35}$ S-methionine and cysteine (5mCi each) were added and the cells incubated at 37°C for another 4 h. The cells were pelleted and resuspended in 1 ml lysis buffer (10mM CHAPS, 1 µg/ml leupeptin, 0.2 mM PMSF, 0.03% sodium azide, 150 mM NaCl, 50 mM Tris-HCl, pH 8.0). Cells were lysed by two cycles of freezing and thawing and the nuclei pelleted by centrifugation at 20,000 x g for 20 min. The supernatant was removed and 100 µl was added to microtiter wells which had been precoated with peptide or the anti-class I MHC antibody PA2.6 (50µg/ml, 200 µl/well, washed and blocked with PBS/2% fetal bovine serum). Six replicate wells were

-48-

set up for each peptide. The plate was incubated on a rotator at 4°C overnight, the supernatant was removed and the wells were each washed twice with PBS/2% fetal bovine serum and once with PBS supplemented with 0.5% Nonidet P-40, 0.1% deoxycholate and 0.05% sodium dodecylsulfate (SDS). The bound proteins were eluted with buffered containing 2% SDS and resolved by 11% SDS-PAGE. For visualization of the labeled proteins, the gel was impregnated with Enhance. The peptide B.2702.75-84 was shown to bind to a molecule of 27kD. In addition, the same residues which were shown to be critical for inhibition of cytolysis by CTL also affected binding to the 27kD molecule.

#### Example 17

##### 15 Peptide Activity in Binding and Cellular Effects

Following the procedures described previously, a number of different peptides were studied as to their activity. Particularly, peptides of the rare HLA-E and G antigens were compared to peptides of the HLA-A and B antigens. The following table indicates the results.

-49-

Table.

PEPTIDE	SEQUENCE	I	II	III	IV	V	VI	VII	VIII
CONS.75-84	RESLRTLRY								
B7.75-84	-----N-----	-	+	-	-	-	-	-	-
B2702.75-84	--N--IALR-	+	+	+	+	+	+	+	+
HLA-E.75-84	-VN-----R-	+	+	+	+	+	+	-	ND
A2.75-84	-VD-G-----	-	-	-	-	-	-	-	-
Bw46.140-155		-	+	-	-	-	ND	ND	ND
HLA-I.222-235		-	+	-	-	-	-	ND	ND
HLA-G	RMNLQTLRGY	ND	+	-	-	+	+	ND	ND

Assays: I = binding of lymphocytes to plates precoated with peptide

II = inhibition of lysis by established CTL

III = blocking of lysis by established CTL

IV = blocking of lysis by fresh NK cells

V = inhibition of proliferation stimulated by Con A

VI = blocking of IL-2 production

VII = precipitation of 27 kD protein

VIII = blocking  $Ca^{2+}$  rise in Jurkat

5

10

15

20

-50-

It is evident from the above results that fragments of the polymorphic regions of Class I MHC antigens can find use in the modulation of CTL activity and other purposes associated with binding of the Class I MHC antigens and proteins which bind to such antigens. The subject compositions may be used for inhibiting CTL toxicity against a target, such as in the case of transplantation, where such activity is undesired. Alternatively, the subject compositions can be used to direct molecules to CTL. Alternatively, the subject compositions may be conjugated to an antigen of interest to activate CTL to lyse cells carrying antigens other than those recognized by the CTL and thus may induce CTL to lyse cells carrying antigens cryptic to the host, as in parasitic diseases and neoplasia. The subject compounds may find use in viral studies to determine MHC sequences associated with restriction of T-cells in the case of viral infection. The peptides may also be used to identify T-cells which specifically bind to the peptides in the context of a particular MHC antigen. Thus, one may isolate subsets of CTL, identify the presence of particular CTL, which may be useful in predicting the success of an allogeneic transplant or whether therapeutic measures are warranted, in investigating tolerization or holes in the repertoire, and the detection of autoimmune disease.

The generic blocking capability of peptide compounds would allow their general use with all HLA types,

particularly with organ transplant recipients. The specific effect of the peptide compounds on the generation of CTL but not on lysis by existing CTL allows for sparing memory responses, while blocking the development of donor specific responses.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

-52-

WHAT IS CLAIMED IS:

1. A peptide comprising at least 10 amino acids coming within the extended sequence:

Q T aa<sup>74</sup> R aa<sup>76</sup> aa<sup>77</sup> L aa<sup>79</sup> aa<sup>80</sup> aa<sup>81</sup> aa<sup>82</sup> aa<sup>83</sup> Y

5 wherein:

aa<sup>74</sup> is D, Y or H;

aa<sup>76</sup> is E, M or V;

aa<sup>77</sup> is D, S, A, G or N;

aa<sup>79</sup> is R, Q or G;

10 aa<sup>80</sup> is T, I or N;

aa<sup>81</sup> is A or L;

aa<sup>82</sup> is R or L;

aa<sup>83</sup> is G or R; by itself, or joined to at least a portion of the sequence WDRETQICKAKA, WDRETQKYKRQA, or  
15 WDRETQISKNTNT.

2. A peptide compound according to Claim 2, comprising at least 10 amino acids coming within the extended sequence:

Q T aa<sup>74</sup> R aa<sup>76</sup> aa<sup>77</sup> L aa<sup>79</sup> aa<sup>80</sup> aa<sup>81</sup> aa<sup>82</sup> aa<sup>83</sup> Y.

20 wherein:

aa<sup>76</sup> is E or V;

aa<sup>79</sup> is R or Q; and

at least one of aa<sup>81</sup> and aa<sup>82</sup> is L.

3. A peptide compound according to Claim 2, wherein said peptide compound is joined at at least one terminus to other than a wild-type sequence of the natural HLA antigen comprising said sequence and when not joined,  
5 terminates with said sequence.

4. A peptide compound according to Claim 1, wherein said peptide compound is joined at at least one terminus to other than a wild-type sequence of the natural HLA antigen comprising said sequence and when not joined,  
10 terminates with said sequence.

5. A peptide compound according to Claim 1, wherein said peptide compound is covalently bonded to a compound capable of providing a detectable signal.

8. A peptide compound of the sequence:  
15 WDRETQICKAKAQTDRENLRIALRY  
or fragment thereof of at least 10 amino acids or said sequence joined at at least one terminus to other than a wild-type sequence of the natural HLA antigen comprising said sequence and when not joined, terminates  
20 with said sequence.

9. A peptide compound of the sequence:  
WDRETQKYKRQAQTDREVSLRNLRGY  
or fragment thereof of at least 10 amino acids or said sequence joined at at least one terminus to other

-54-

than a wild-type sequence of the natural HLA antigen comprising said sequence and when not joined, terminates with said sequence.

10. A peptide compound of the sequence:

5                   WDRETQISKTNLTQTYRESLRNLRGY

or fragment thereof of at least 10 amino acids or said sequence joined at at least one terminus to other than a wild-type sequence of the natural HLA antigen comprising said sequence and when not joined, terminates  
10 with said sequence.

11. A peptide compound of not greater than 30 amino acids including a sequence:

15                   RENLRIALRY;  
                  RESLRNLRGY;  
                  RVNLRRTLRRY;  
                  RMNLQTLRGY  
                  REDLRTLRLRY; or  
                  WDRETQICKA.

12. A method of modulating cytolytic activity of a  
20 CTL, said method comprising:

combining CTL with a peptide compound in an amount to modulate cytolytic activity, said peptide compound characterized by being of at least 8 amino acids and



-55-

having a sequence of the human Class I HLA  $\alpha$ 1-domain and coming within the extended sequence:

Q T aa<sup>74</sup> R aa<sup>76</sup> aa<sup>77</sup> L aa<sup>79</sup> aa<sup>80</sup> aa<sup>81</sup> aa<sup>82</sup> aa<sup>83</sup> Y

wherein:

5 aa<sup>74</sup> is D, Y or H;

aa<sup>76</sup> is E, M or V;

aa<sup>77</sup> is D, S or N;

aa<sup>79</sup> is R, Q or G;

aa<sup>80</sup> is T, I or N;

10 aa<sup>81</sup> is A or L;

aa<sup>82</sup> is R or L;

aa<sup>83</sup> is G or R; by itself, or joined to at least a portion of the sequence WDRETQICKAKA, WDRETQKYKRQA, or WDRETQISKNTNT.

15 13. A method according to Claim 12, wherein said peptide compound is joined at at least one terminus to other than a wild-type sequence of the natural HLA antigen comprising said sequence and when not joined, terminates with said sequence.

20 14. A method according to Claim 11, wherein said peptide compound is of the sequence:

WDRETQICKAKAQTDRENLRNALRY;

WDRETQKYKRQAQTDREVSLRNLRGY; or

WDRETQISKNTNTQTYRESLRNLRGY;

-56-

or fragment thereof of at least 10 amino acids or  
said sequence joined at at least one terminus to other  
than a wild-type sequence of the natural HLA antigen  
comprising said sequence and when not joined, terminates  
5 with said sequence.

15. A method according to Claim 11, wherein said  
peptide comprises amino acids 75-84 of an HLA-B antigen.

16. A method of blocking differentiation of CTL,  
said method comprising:

10 contacting CTL with a peptide having the sequence;

R E N L R I A L R Y;

R E S L R N L R G Y;

R V N L R T L R R Y;

R M N L Q T L R G Y

15 R E D L R T L L R Y; or

W D R E T Q I C K A;

in an amount sufficient to block differentiation.

17. A protein in substantially pure form  
characterized by:

20 expressed in CD8+ T cells;

binds to a peptide having a sequence:

-57-

R E N L R I A L R Y ;

R E S L R N L R G Y ;

R V N L R T L R R Y ;

R M N L Q T L R G Y

5

R E D L R T L L R Y ; and

associated with the regulation of cytolytic activity  
of CTL's.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US93/01758

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(5) :A61K 37/02; C07K 5/00, 7/00, 15/00, 17/00 US CL :530/324, 325, 326, 327, 328, 329 According to International Patent Classification (IPC) or to both national classification and IPC																				
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 530/324, 325, 326, 327, 328, 329 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS, sequence search, medline, biosis																				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>																				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
Y	BIOCHEMISTRY, Volume 22, issued May 1983, J.A. Lopex de Castro et al., "Primary Structure of Papain-Solubilized Human Histocompatibility Antigen HLA-B40 (-Bw60). An Outline of Alloantigenic Determinants," pages 3961-3969, see the entire document.	1-17																		
Y	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, volume 82, issued April 1985, M.A. Vega et al., "Structural Analysis of an HLA-B27 functional variant: Identification of Residues that Contribute to the Specificity of Recognition by Cytolytic T Lymphocytes," pages 7394-7398, see entire document.	1-17																		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>T</td> <td>Inter document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be part of particular relevance</td> <td>X*</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*E* earlier document published on or after the international filing date</td> <td>Y*</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>X*</td> <td>document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:	T	Inter document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be part of particular relevance	X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*E* earlier document published on or after the international filing date	Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	X*	document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means			*P* document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	T	Inter document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
*A* document defining the general state of the art which is not considered to be part of particular relevance	X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
*E* earlier document published on or after the international filing date	Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	X*	document member of the same patent family																		
*O* document referring to an oral disclosure, use, exhibition or other means																				
*P* document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search 12 August 1993		Date of mailing of the international search report <b>16 AUG 1993</b>																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231		Authorized officer <i>David R. Preston</i> DAVID R. PRESTON																		
Facsimile No. NOT APPLICABLE		Telephone No. (703) 308-0196																		

**INTERNATIONAL SEARCH REPORT**International application No.  
PCT/US93/01758**C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	THE JOURNAL OF IMMUNOLOGY, Vol. 134, No. 4, issued April 1985, B.H. Koller et al., "Cloning and Complete Sequence of an HLA-A2 Gene: Analysis of Two HLA-A Alleles at the Nucleotide Level," pages 2727-2733, see the entire document.	1-17